MCID: HMT002
MIFTS: 64

Hematologic Cancer

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Hematologic Cancer

MalaCards integrated aliases for Hematologic Cancer:

Name: Hematologic Cancer 12 55 15 38
Hematologic Neoplasm 12 29 6
Hematologic Malignancies 55 15
Hematologic Neoplasms 44 72
Hematopoietic and Lymphoid System Tumor 12
Malignant Hematopoietic Neoplasm 12
Hematopoietic Neoplasms 72
Hematologic Malignancy 12
Hematopoietic Neoplasm 12
Hematological Tumors 12
Hematopoietic Cancer 12
Hematopoietic Tumors 12
Blood Cancer 12
Liquid Tumor 72

Classifications:



External Ids:

Disease Ontology 12 DOID:2531
MeSH 44 D019337
NCIt 50 C27134
UMLS 72 C0376544 C0376545 C3890429

Summaries for Hematologic Cancer

Disease Ontology : 12 An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.

MalaCards based summary : Hematologic Cancer, also known as hematologic neoplasm, is related to bone marrow cancer and 8p11 myeloproliferative syndrome. An important gene associated with Hematologic Cancer is ETV6 (ETS Variant Transcription Factor 6), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Endometrial cancer. The drugs Basiliximab and Meropenem have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Related Diseases for Hematologic Cancer

Diseases related to Hematologic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 846)
# Related Disease Score Top Affiliating Genes
1 bone marrow cancer 33.7 RUNX1 MPL KMT2A KIT JAK2 IL3
2 8p11 myeloproliferative syndrome 33.4 RUNX1 KIT FLT3
3 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 33.2 RUNX1 KMT2A KIT FLT3 ETV6
4 leukemia, acute myeloid 32.5 WT1 RUNX1 NUP98 MPL MLLT10 KMT2A
5 lymphocytic leukemia 32.3 RUNX1 KMT2A IL2 ETV6
6 aplastic anemia 32.3 MPL IL3 IL2 FLT3 CSF2
7 myeloma, multiple 32.2 PVT1 KIT JAK2 IL2 CSF2
8 refractory anemia 32.2 RUNX1 MPL JAK2 IL3
9 leukemia 32.2 WT1 RUNX1 MPL KIT JAK2 FLT3
10 acute leukemia 32.2 WT1 RUNX1 MLLT10 KMT2A KIT JAK2
11 myelodysplastic syndrome 32.1 WT1 RUNX1 NUP98 MPL KMT2A KIT
12 myeloid leukemia 32.1 WT1 RUNX1 NUP98 KIT JAK2 IL3
13 leukemia, acute lymphoblastic 32.0 RUNX1 KMT2A FLT3 ETV6 ABL1
14 myeloid sarcoma 32.0 KMT2A KIT FLT3
15 leukemia, acute monocytic 31.9 NUP98 MLLT10 KMT2A
16 juvenile myelomonocytic leukemia 31.8 RUNX1 JAK2 FLT3 CSF2 CBL
17 leukemia, chronic myeloid 31.8 WT1 RUNX1 NUP98 MPL KMT2A KIT
18 lymphoma, non-hodgkin, familial 31.7 JAK2 IL3 IL2 CSF2
19 blood platelet disease 31.7 RUNX1 MPL JAK2
20 thrombocytosis 31.6 MPL JAK2 IL3 CSF2
21 precursor t-cell acute lymphoblastic leukemia 31.6 NUP98 MLLT10 KMT2A FLT3 ETV6 ABL1
22 myelofibrosis 31.5 MPL KIT JAK2 IL3 FLT3
23 megakaryocytic leukemia 31.5 RUNX1 JAK2 IL3 CSF2
24 chronic myelomonocytic leukemia 31.4 RUNX1 KIT JAK2 FLT3 ETV6 CSF2
25 renal cell carcinoma, nonpapillary 31.4 WT1 PVT1 PTHLH KIT IL2 FLT3
26 leukemia, acute lymphoblastic 3 31.3 RUNX1 KMT2A FLT3 ETV6 ABL1
27 polycythemia vera 31.3 MPL KIT JAK2 IL3 ABL1
28 chronic eosinophilic leukemia 31.3 WT1 KIT FLT3 ABL1
29 neutrophilia, hereditary 31.3 PTHLH JAK2 FLT3 CSF2
30 myeloproliferative neoplasm 31.3 MPL KIT JAK2 ABL1
31 polycythemia 31.3 MPL JAK2 IL3
32 childhood leukemia 31.3 RUNX1 KMT2A ETV6 ABL1
33 acute promyelocytic leukemia 31.2 WT1 RUNX1 PVT1 IL3 FLT3
34 essential thrombocythemia 31.2 MPL JAK2 IL3 ABL1
35 acute myeloblastic leukemia with maturation 31.2 KIT FLT3
36 gastrointestinal stromal tumor 31.2 KIT FLT3 CCDC26 ABL1
37 severe congenital neutropenia 31.2 JAK2 IL3 CSF2
38 malignant glioma 31.1 XIST PVT1 CCDC26
39 pancytopenia 31.1 MPL IL3 CSF2
40 hypereosinophilic syndrome 31.1 KIT IL3 CSF2 ABL1
41 diphtheria 30.9 IL3 IL2 CSF2
42 retinitis pigmentosa and erythrocytic microcytosis 30.8 JAK2 IL3
43 sarcoidosis 1 30.7 IL3 IL2 CSF2
44 central nervous system hematologic cancer 12.5
45 refractory hematologic cancer 12.5
46 obsolete: hereditary thrombocytopenia-hematological cancer predisposition syndrome 12.3
47 myeloproliferative/lymphoproliferative neoplasms, familial 11.9
48 mismatch repair cancer syndrome 11.7
49 adult t-cell leukemia 11.5
50 fusariosis 11.5

Graphical network of the top 20 diseases related to Hematologic Cancer:



Diseases related to Hematologic Cancer

Symptoms & Phenotypes for Hematologic Cancer

GenomeRNAi Phenotypes related to Hematologic Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.1 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.1 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.1 ABL1 FLT3 KIT

MGI Mouse Phenotypes related to Hematologic Cancer:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 ABL1 CBL CSF2 ETV6 FLT3 IL2
2 growth/size/body region MP:0005378 10.36 ABL1 CBL CSF2 ETV6 FLT3 IL2
3 hematopoietic system MP:0005397 10.34 ABL1 CBL CSF2 ETV6 FLT3 IL2
4 immune system MP:0005387 10.3 ABL1 CBL CSF2 ETV6 FLT3 IL2
5 homeostasis/metabolism MP:0005376 10.29 ABL1 CBL CSF2 ETV6 FLT3 IL2
6 cardiovascular system MP:0005385 10.26 ABL1 CBL CSF2 ETV6 IL2 KIT
7 endocrine/exocrine gland MP:0005379 10.26 ABL1 CBL CSF2 ETV6 FLT3 IL2
8 embryo MP:0005380 10.24 ABL1 CSF2 ETV6 JAK2 KIT KMT2A
9 mortality/aging MP:0010768 10.21 ABL1 CBL CSF2 ETV6 FLT3 IL2
10 liver/biliary system MP:0005370 10.06 ABL1 CBL IL2 JAK2 KIT KMT2A
11 integument MP:0010771 10.03 CBL CSF2 ETV6 JAK2 KIT KMT2A
12 neoplasm MP:0002006 10.02 CSF2 ETV6 FLT3 IL2 JAK2 KIT
13 no phenotypic analysis MP:0003012 9.8 ETV6 FLT3 IL2 KIT KMT2A RUNX1
14 normal MP:0002873 9.76 ABL1 ETV6 JAK2 KIT KMT2A PTHLH
15 respiratory system MP:0005388 9.56 ABL1 CBL CSF2 IL2 KIT PTHLH
16 skeleton MP:0005390 9.28 ABL1 CBL CSF2 FLT3 JAK2 KIT

Drugs & Therapeutics for Hematologic Cancer

Drugs for Hematologic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 546)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
2
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 64778 441130
3
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
4
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
5
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
6
Zinc Approved, Investigational Phase 4 7440-66-6 32051
7
Protein C Approved Phase 4
8
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
9
Busulfan Approved, Investigational Phase 4 55-98-1 2478
10
Bortezomib Approved, Investigational Phase 4 179324-69-7 93860 387447
11
Ofloxacin Approved Phase 4 82419-36-1 4583
12
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
13
Liraglutide Approved Phase 4 204656-20-2 44147092
14
Glucagon Approved Phase 4 16941-32-5
15
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
16
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
17
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
18
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
19 Lactams Phase 4
20 penicillins Phase 4
21 beta-Lactams Phase 4
22 Epoetin alfa Phase 4 113427-24-0
23 Drotrecogin alfa activated Phase 4
24 Thymoglobulin Phase 4
25 Antilymphocyte Serum Phase 4
26 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
27 Cyclooxygenase Inhibitors Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29 Glucagon-Like Peptide 1 Phase 4
30 Incretins Phase 4
31 Hypoglycemic Agents Phase 4
32 Cyclooxygenase 2 Inhibitors Phase 4
33 Antiparasitic Agents Phase 4
34 Antiprotozoal Agents Phase 4
35 Pharmaceutical Solutions Phase 4
36 14-alpha Demethylase Inhibitors Phase 4
37 Cytochrome P-450 CYP3A Inhibitors Phase 4
38 Cytochrome P-450 Enzyme Inhibitors Phase 4
39 Steroid Synthesis Inhibitors Phase 4
40 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
41 Liposomal amphotericin B Phase 4
42
Hydroxyitraconazole Phase 4
43
Imiquimod Approved, Investigational Phase 2, Phase 3 99011-02-6 57469
44
Tazobactam Approved Phase 3 89786-04-9 123630
45
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
46
Piperacillin Approved Phase 3 66258-76-2 43672
47
Naproxen Approved, Vet_approved Phase 3 22204-53-1 1302 156391
48
Denosumab Approved Phase 3 615258-40-7
49
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
50
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884

Interventional clinical trials:

(show top 50) (show all 1296)
# Name Status NCT ID Phase Drugs
1 Pilot Study About Viability and Efficacy of Intrabone Administration of Umbilical Cord Blood for Allogeneic Stem Cell Transplantation Unknown status NCT00838019 Phase 4
2 Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants Unknown status NCT01339988 Phase 4 Busulfan/Cyclophosphamide
3 Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Unknown status NCT02677181 Phase 4 ATG;CsA;mycophenolate mofetil;Methotrexate
4 Prospective Unblinded Randomized Trial to Examine Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia Unknown status NCT02463747 Phase 4 Piperacillin/tazobactam;Ceftazidim;Meropenem;Vancomycin
5 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
6 Optimizing Treatment of the Anaemia in Onco-Hematological Diseases With NeoRecormon 30,000 IU Once Weekly Completed NCT02564094 Phase 4 Epoetin beta
7 Phase IV, Compassionate Use Program of Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4 Rasburicase
8 A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone;Melphalan;G-CSF;Cyclophosphamide;Mesna
9 An Open-label Non-randomized Phase IV Trial of the Clinical Efficacy of Intravenously Administered 1000mg Paracetamol as Antipyretic and Analgesic Medication Completed NCT01070732 Phase 4 Paracetamol
10 A Ramdomized Double Blined Placebo Controlled Oral Zinc Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Stem Cell Support Completed NCT00449592 Phase 4 Zinc;Placebo
11 A Prospective, Randomized Trial Comparing the Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing Completed NCT01416025 Phase 4 Prospective TDM Arm
12 Early Application of CPAP in Hematologic Neutropenic Patients Avoid Acute Respiratory Failure Completed NCT00507533 Phase 4
13 A Safety Evaluation of Xigris Drotrecogin Alfa Activated in Hematopoietic Stem Cell Transplant Patients With Severe Sepsis Completed NCT00067730 Phase 4 Drotrecogin Alfa (activated)
14 AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study. Completed NCT00334412 Phase 4 Ambisome;caspofungin
15 A New Dosing Regimen for Posaconazole Prophylaxis in Children Based in Body Surface Area Completed NCT02372357 Phase 4 Posaconazole prophylaxis 120 mg/m² tid
16 A Randomized Clinical Study of the Decolonization of MDR Gram-negative Bacteria in Patients With Haematological Malignancies Completed NCT02966457 Phase 4 Colistimethate Sodium
17 Busulfan Dose Escalation Study Based on AUC in the Setting of Busulfan/Fludarabine Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
18 Multicenter, Randomised Study of the Use of Non-Invasive Ventilation (NIV) Versus Oxygen Therapy (O2) in Reducing Dyspnea in End-stage Solid Cancer Patients With Respiratory Failure and Distress Completed NCT00533143 Phase 4
19 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
20 Human Papillomavirus Antibody Response After GARDASIL 9 Vaccination in Patients After Allogeneic Stem Cell Transplantation Recruiting NCT03023631 Phase 4
21 A Multicenter Study to Explore the Mechanism of Acquired Immune Escape In Patients With Metastatic Cancer Progressing on Checkpoint Inhibitor Therapy Recruiting NCT03333655 Phase 4
22 Shanghai General Hospital Affiliated to Shanghai Jiao Tong University Recruiting NCT03608059 Phase 4 ATG/PTCy;standard ATG;standard PTCy
23 Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease Recruiting NCT03844360 Phase 4 Bortezomib;Eltrombopag;Imatinib;dasatinib;Pegaspargase;Anti-Infective Drugs
24 RDD Versus VDD Followed by ASCT in Newly Diagnosed Young Patients With Multiple Myeloma Recruiting NCT03908138 Phase 4 RDD;VDD
25 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
26 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
27 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Enrolling by invitation NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
28 Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA) Not yet recruiting NCT02920190 Phase 4 Liraglutide
29 The Impact of Genotype on Plasma and Cerebral Spinal Fluid Pharmacokinetics of Celecoxib in Children Not yet recruiting NCT01344200 Phase 4 Celecoxib
30 The Strategy Antifungal Empirical Traditional is Again Justified in Prolonged Neutropenias ". Study "PREVERT" Terminated NCT00190463 Phase 4 Amphotericin B
31 A Multicenter, Randomized Trial Comparing The Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Subjects With Hematological Malignancy Terminated NCT02895529 Phase 4 Itraconazole;Caspofungin
32 A Pilot/Feasibility Study of Ledipasvir/Sofosbuvir as Treatment for Hepatitis C in Hematopoietic Cell Transplantation (HCT) Recipients. Withdrawn NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
33 Evaluation of Benefit and Side Effects of Double Umbilical Cord Blood Units Stem Cell Transplantation in Hematologic Malignancies Unknown status NCT01015742 Phase 2, Phase 3 Stem cell Transplantation
34 Phase III Trial of 6 Weeks of Imiquimod for the Treatment of Bowens Disease of the Head and Neck. Outcome is Histologic Clearance at 14 Weeks. Unknown status NCT00384124 Phase 2, Phase 3 Imiquimod
35 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
36 Combination of Ibrutinib and As2O3 in the Treatment of CLL Unknown status NCT02757040 Phase 3 Ibrutinib combined with As2O3;ibrutinib
37 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
38 Multi-Centre Prospective Randomized Study on the Use of Two Different Doses of Rabbit Anti-Thymocyte Globulin for GVHD Prevention in Paediatric Patients With Haematological Malignancies Given an Unrelated Donor Haematopoietic Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
39 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
40 A Randomized, Open-Label, Multi-Center, Comparative Study of the Efficacy and Safety of Piperacillin/Tazobactam to Cefepime for the Empiric Treatment of Neutropenic Fever in Patients With a Hematologic Malignancy or Lymphoma Completed NCT00044759 Phase 3 Piperacillin/Tazobactam (Tazocin)
41 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
42 Kinetics of 1, 3 Beta-d- Glucan Assay in Patients With Hematologic Malignancies Receiving Voriconazole Prophylaxis Completed NCT00904995 Phase 3 Voriconazole;Voriconazole
43 Prevention of Pegfilgrastim-Induced Bone Pain (PIBP): A Phase III Double-Blind Placebo-Controlled Clinical Trial Completed NCT00602420 Phase 3 naproxen
44 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients With Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly Completed NCT01437787 Phase 3 SAR302503;Placebo
45 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
46 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
47 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT01530581 Phase 3
48 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma Completed NCT01345019 Phase 3 Denosumab;Zoledronic acid;Placebo to Denosumab;Placebo to zoledronic acid
49 A 1-Year, Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Cord Blood Cells Expanded With MPCs for Hematopoetic Recovery in Patients With Hematologic Malignancies After Myeloablative Treatment Completed NCT01854567 Phase 3
50 Multi-center, Open Label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia (BMT CTN #0501) Completed NCT00412360 Phase 3 Cyclophosphamide;Fludarabine;Cyclosporine A;Mycophenolate Mofetil

Search NIH Clinical Center for Hematologic Cancer

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hematologic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hematologic Cancer:
ALD-151, umbilical cord blood cells for hematologic and immunodefeciency diseases
Allocord, cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Co-infusion of umbilical cord blood and haploidentical CD34+ cells for hematological diseases
Ducord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Expanded cord blood hematopoietic stem cells for hematologic malignancies
Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Hematopoietic stem cells for treatment of hematologic malignancies
StemEx, umbilical cord blood stem/progenitor cells for hematological diseases
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Embryonic/Adult Cultured Cells Related to Hematologic Cancer:
Umbilical cord blood ALDH+ cells (ALD-151) PMIDs: 10430905
Umbilical cord blood-derived hematopoietic progenitor cells (Allocord) PMIDs: 11953027
Peripheral blood-derived hematopoietic stem cells
Umbilical cord blood-derived hematopoietic progenitor cells (Ducord) PMIDs: 22698485 21810098 21277377 23711284
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 21396596
Expanded umbilical cord blood-derived hematopoietic stem cells PMIDs: 21396596
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD) PMIDs: 9828244
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724
Umbilical cord blood-derived hematopoietic stem cells (family) PMIDs: 20676147

Cochrane evidence based reviews: hematologic neoplasms

Genetic Tests for Hematologic Cancer

Genetic tests related to Hematologic Cancer:

# Genetic test Affiliating Genes
1 Hematologic Neoplasm 29 H3C2

Anatomical Context for Hematologic Cancer

MalaCards organs/tissues related to Hematologic Cancer:

41
T Cells, Bone, Bone Marrow, Myeloid, B Cells, Testes, Lung

Publications for Hematologic Cancer

Articles related to Hematologic Cancer:

(show top 50) (show all 916)
# Title Authors PMID Year
1
Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors. 9 38
16788155 2006
2
Plasma PTH and PTH-rP levels and clodronate therapy in cancer patients with hypercalcemia. 9 38
7910069 1993
3
Individual and Dyadic Coping and Fear of Progression in Mothers and Fathers of Children with Hematologic Cancer. 38
31408204 2019
4
Temporal Trends in the Use of Acute Recanalization Therapies for Ischemic Stroke in Patients with Cancer. 38
31153762 2019
5
A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. 38
31350306 2019
6
Neurophysiological evidence of impaired attention and working memory in untreated hematologic cancer patients. 38
31163369 2019
7
Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically-heterogeneous mouse model of T-cell acute lymphoblastic leukemia. 38
31399482 2019
8
Correction: AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. 38
31262746 2019
9
Discovery of pyrazole-thiophene derivatives as highly Potent, orally active Akt inhibitors. 38
31301565 2019
10
"I Am Sure That They Use My PROM Data for Something Important." A Qualitative Study About Patients' Experiences From a Hematologic Outpatient Clinic. 38
31361675 2019
11
Disruption of NOTCH signaling by a small molecule inhibitor of the transcription factor RBPJ. 38
31346210 2019
12
Specific inhibition of DPY30 activity by ASH2L-derived peptides suppresses blood cancer cell growth. 38
31251903 2019
13
Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches. 38
31216696 2019
14
A prospective study examining cachexia predictors in patients with incurable cancer. 38
31164115 2019
15
Relevant updates in systemic mastocytosis. 38
30978435 2019
16
Biomicrofluidic Systems for Hematologic Cancer Research and Clinical Applications. 38
31173533 2019
17
Loss of KDM6A confers drug resistance in acute myeloid leukemia. 38
31201358 2019
18
I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma. 38
30455393 2019
19
Using Prognosis-Related Gene Expression Signature and Connectivity Map for Personalized Drug Repositioning in Multiple Myeloma. 38
31048671 2019
20
Primary and Secondary Breast Lymphoma: Clinical, Pathologic, and Multimodality Imaging Review. 38
30924754 2019
21
Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies. 38
30467206 2019
22
The relationship between acceptance, fatigue, and subjective cognitive impairment in hematologic cancer survivors. 38
31193118 2019
23
Effect of Collaborative Telerehabilitation on Functional Impairment and Pain Among Patients With Advanced-Stage Cancer: A Randomized Clinical Trial. 38
30946436 2019
24
ICA-EMA: A Tool for Assessing Nursing Complexity of Patients With Oncohematologic Disease in an Italian Center. 38
31085671 2019
25
The Ambivalent Role of lncRNA Xist in Carcinogenesis. 38
30685833 2019
26
Bayesian modeling of hematologic cancer and vehicular air pollution among young people in the city of São Paulo, Brazil. 38
31025573 2019
27
A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease. 38
30917949 2019
28
Illness Uncertainties Tied to Developmental Tasks Among Young Adult Survivors of Hematologic Cancers. 38
30489197 2019
29
Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors. 38
30824167 2019
30
Biological effects of whole Z.Officinale extract on chronic myeloid leukemia cell line K562. 38
30684525 2019
31
Correction: Effect of an Inpatient Rehabilitation Program for Recovery of Deconditioning in Hematologic Cancer Patients After Chemotherapy. 38
31072092 2019
32
The Antioxidant from Ethanolic Extract of Rosa cymosa Fruits Activates Phosphatase and Tensin Homolog In Vitro and In Vivo: A New Insight on Its Antileukemic Effect. 38
31010164 2019
33
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. 38
31018069 2019
34
FLT3/ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways. 38
30975911 2019
35
Clonal hematopoiesis and preleukemia-Genetics, biology, and clinical implications. 38
30939217 2019
36
Risk for depression and anxiety in long-term survivors of hematologic cancer. 38
30762398 2019
37
The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma. 38
30537552 2019
38
Mesenchymal stem cells in suppression or progression of hematologic malignancy: current status and challenges. 38
30705410 2019
39
Prevalence, Underlying Causes, and Preventability of Sepsis-Associated Mortality in US Acute Care Hospitals. 38
30768188 2019
40
Nanogels Enable Efficient miRNA Delivery and Target Gene Downregulation in Transfection-Resistant Multiple Myeloma Cells. 38
30571914 2019
41
Residential ambient benzene exposure in the United States and subsequent risk of hematologic malignancies. 38
30737780 2019
42
Corticosteroid therapy alone for the treatment of C3 glomerulonephritis in association with monoclonal gammopathy
. 38
30474593 2019
43
Relapsed Acute Lymphoblastic Leukemia Presenting as Acute Renal Failure. 38
31214367 2019
44
Invasive Fungal Infection in Febrile Patients with Hematologic Malignancies Undergoing Chemotherapy in Iran. 38
30747087 2019
45
Catheter-related bloodstream infections with coagulase-negative staphylococci: are antibiotics necessary if the catheter is removed? 38
30719282 2019
46
Agressive NK-cell leukemia in a pediatric patient. 38
31303650 2019
47
Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study. 38
30534946 2019
48
Polypharmacy, limited activity, fatigue and insomnia are the most frequent symptoms and impairments in older hematological cancer survivors (70+): Findings from a register-based study on physical and mental health. 38
29880406 2019
49
High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles. 38
30693332 2019
50
Sporotrichosis In Immunocompromised Hosts. 38
30641918 2019

Variations for Hematologic Cancer

ClinVar genetic disease variations for Hematologic Cancer:

6 (show all 18)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 CBL NM_005188.3(CBL): c.1111T> C (p.Tyr371His) single nucleotide variant Pathogenic rs267606706 11:119148891-119148891 11:119278181-119278181
2 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic rs121913506 4:55599320-55599320 4:54733154-54733154
3 ETV6 NM_001987.4(ETV6): c.1106G> A (p.Arg369Gln) single nucleotide variant Pathogenic rs724159946 12:12037475-12037475 12:11884541-11884541
4 ETV6 NM_001987.4(ETV6): c.1195C> T (p.Arg399Cys) single nucleotide variant Pathogenic rs724159945 12:12038902-12038902 12:11885968-11885968
5 insertion Pathogenic
6 Translocation Pathogenic
7 MPL NM_005373.2(MPL): c.1544G> T (p.Trp515Leu) single nucleotide variant Pathogenic rs121913615 1:43815009-43815009 1:43349338-43349338
8 CBL NM_005188.3(CBL): c.1150T> C (p.Cys384Arg) single nucleotide variant Pathogenic/Likely pathogenic rs387906664 11:119148930-119148930 11:119278220-119278220
9 ETV6 NM_001987.4(ETV6): c.641C> T (p.Pro214Leu) single nucleotide variant Pathogenic/Likely pathogenic rs724159947 12:12022535-12022535 12:11869601-11869601
10 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 4:55599320-55599320 4:54733154-54733154
11 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 4:55594221-55594221 4:54728055-54728055
12 CSF1R NM_005211.3(CSF1R): c.1711T> G (p.Tyr571Asp) single nucleotide variant Likely pathogenic rs1057519802 5:149441328-149441328 5:150061765-150061765
13 CSF1R NM_005211.3(CSF1R): c.2906A> T (p.Tyr969Phe) single nucleotide variant Likely pathogenic rs1801271 5:149433645-149433645 5:150054082-150054082
14 CSF1R NM_005211.3(CSF1R): c.2906A> G (p.Tyr969Cys) single nucleotide variant Likely pathogenic rs1801271 5:149433645-149433645 5:150054082-150054082
15 CSF1R NM_005211.3(CSF1R): c.2905T> C (p.Tyr969His) single nucleotide variant Likely pathogenic rs121913393 5:149433646-149433646 5:150054083-150054083
16 CSF1R NM_005211.3(CSF1R): c.902T> C (p.Leu301Ser) single nucleotide variant Likely pathogenic rs121913390 5:149453044-149453044 5:150073481-150073481
17 CSF1R NM_005211.3(CSF1R): c.903G> T (p.Leu301Phe) single nucleotide variant Likely pathogenic rs1057520014 5:149453043-149453043 5:150073480-150073480
18 KIT NM_000222.2(KIT): c.2447A> T (p.Asp816Val) single nucleotide variant Uncertain significance rs121913507 4:55599321-55599321 4:54733155-54733155

Expression for Hematologic Cancer

Search GEO for disease gene expression data for Hematologic Cancer.

Pathways for Hematologic Cancer

Pathways related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 NUP98 KIT JAK2 IL3 IL2 FLT3
2
Show member pathways
12.69 RUNX1 KIT IL3 FLT3 CSF2 CBL
3 12.48 RUNX1 KIT JAK2 IL3 IL2 FLT3
4
Show member pathways
12.39 IL3 IL2 CSF2 CBL
5 12.32 RUNX1 MPL KIT JAK2 IL3 IL2
6
Show member pathways
12.27 KIT IL3 IL2 FLT3 CBL
7
Show member pathways
12.2 JAK2 IL3 FLT3 CBL
8
Show member pathways
12.16 MPL JAK2 IL3 IL2 CSF2 ABL1
9
Show member pathways
12.04 KIT JAK2 IL3 CBL
10
Show member pathways
12.01 JAK2 IL3 IL2 CSF2
11 11.94 KIT JAK2 FLT3 CBL ABL1
12 11.74 JAK2 IL3 IL2 ABL1
13 11.74 KIT IL3 FLT3 CSF2
14 11.67 RUNX1 KIT IL2
15
Show member pathways
11.64 IL3 IL2 CSF2
16 11.6 KIT IL2 FLT3 CSF2
17 11.55 WT1 IL2 ABL1
18 11.5 MPL KIT IL3 IL2 FLT3 CSF2
19 11.44 WT1 RUNX1 KMT2A IL3 FLT3 ETV6
20 11.4 RUNX1 IL3 CSF2
21 11.12 IL3 IL2 CSF2
22 10.9 KIT IL3 IL2 FLT3 CSF2
23 10.81 KIT CBL

GO Terms for Hematologic Cancer

Biological processes related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.87 PTHLH KIT JAK2 IL3 IL2 FLT3
2 male gonad development GO:0008584 9.79 WT1 KIT CBL
3 negative regulation of apoptotic process GO:0043066 9.77 WT1 IL2 CBL
4 protein autophosphorylation GO:0046777 9.76 KIT JAK2 FLT3 ABL1
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.73 JAK2 IL3 ABL1
6 MAPK cascade GO:0000165 9.73 KIT JAK2 IL3 IL2 FLT3 CSF2
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.71 KIT JAK2 FLT3 CBL
8 hemopoiesis GO:0030097 9.7 RUNX1 KIT FLT3
9 regulation of regulatory T cell differentiation GO:0045589 9.61 RUNX1 IL2
10 regulation of hematopoietic stem cell differentiation GO:1902036 9.61 RUNX1 KMT2A ABL1
11 negative regulation of cell-cell adhesion GO:0022408 9.59 JAK2 ABL1
12 interleukin-6-mediated signaling pathway GO:0070102 9.58 JAK2 CBL
13 mast cell degranulation GO:0043303 9.58 KIT CBL
14 hematopoietic stem cell proliferation GO:0071425 9.57 RUNX1 ETV6
15 cytokine-mediated signaling pathway GO:0019221 9.56 MPL KIT JAK2 IL3 IL2 FLT3
16 dendritic cell differentiation GO:0097028 9.55 FLT3 CSF2
17 regulation of myeloid cell differentiation GO:0045637 9.54 RUNX1 CSF2
18 embryonic hemopoiesis GO:0035162 9.54 KMT2A KIT IL3
19 negative regulation of heart contraction GO:0045822 9.51 JAK2 IL2
20 regulation of cytokine-mediated signaling pathway GO:0001959 9.49 RUNX1 IL3
21 myeloid progenitor cell differentiation GO:0002318 9.48 KIT FLT3
22 peptidyl-tyrosine phosphorylation GO:0018108 9.46 KIT JAK2 FLT3 ABL1
23 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.1 KIT JAK2 IL3 IL2 FLT3 CSF2

Molecular functions related to Hematologic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.55 WT1 RUNX1 MLLT10 KMT2A ETV6
2 peptide hormone receptor binding GO:0051428 8.96 PTHLH JAK2
3 protein tyrosine kinase activity GO:0004713 8.92 KIT JAK2 FLT3 ABL1

Sources for Hematologic Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....